Ensovibep passed an important test. Molecular Partners from Schlieren and Novartis are now striving for emergency approval.

The Swiss company Molecular Partners reports a breakthrough in their Covid medication.

That's what it's about

  • The Covid drug from the Swiss company Molecular Partners has passed an important hurdle.

  • The drug Ensovibep can significantly reduce the risk of hospitalization .

  • Now it should get emergency approval.

There is good news from Switzerland in the fight against the coronavirus: The corona drug Ensovibep from Schlierem-based bio-tech company Molecular Partners has achieved its goals in a phase II study, according to a press release. Ensovibep has clearly reduced the viral load.

The study showed a significant reduction of around 80 percent in hospital stays and visits to the emergency room. The drug also works against Omikron. In addition, it is safe and well tolerated in all doses.

Emergency approval should come

Novartis is now trying to get emergency approval for the drug, first in the US and then worldwide. As a license partner, Novartis is responsible for the development, manufacture, sale and commercialization of Ensovibep.

Molecular Partners will receive 150 million Swiss francs from Novartis if the phase II study passes, and then 22 percent on the Sales generated by Novartis with the drug. The federal government has already secured 200,000 doses of the drug, according to various media reports.

BAG is negotiating with Pfizer about new corona miracle pill Paxlovid

A new corona drug from Pfizer also gives cause for hope: Paxlovid has already received emergency approval. The FOPH is in talks with Pfizer so that the drug can also be used in Switzerland.

My 20 Minuten

As a member, you become part of the 20-Minuten community and benefit from great benefits and exclusive competitions every day!

Your opinion

By Teresa Tapmleton

Teresa Tampleton has been a reporter on the news desk since 2018. Before that she wrote about young adolescence and family dynamics for Styles and was the legal affairs correspondent for the Metro desk. Before joining The Nizh TEkegram, Teresa Tampleton worked as a staff writer at the Village Voice and a freelancer for Newsday, The Wall Street Journal, GQ and Mirabella. To get in touch, contact me through my teresa@ntelegram.com 1-800-268-7341

Leave a Reply

Your email address will not be published.